Last reviewed · How we verify
Nasal Decongestant
Nasal decongestants work by constricting blood vessels in the nasal mucosa to reduce swelling and improve airflow.
Nasal decongestants reduce nasal congestion by constricting blood vessels in the nasal mucosa, thereby decreasing swelling and improving airflow. Used for Nasal congestion due to common cold, allergies, or sinusitis.
At a glance
| Generic name | Nasal Decongestant |
|---|---|
| Also known as | nasally applied α-sympathomimetics |
| Sponsor | Engelhard Arzneimittel GmbH & Co.KG |
| Drug class | Sympathomimetic decongestant |
| Target | Alpha-adrenergic receptors (likely alpha-1) |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
These agents are typically sympathomimetic amines that bind to alpha-adrenergic receptors on nasal blood vessels, causing vasoconstriction. This reduces mucosal edema and congestion, thereby improving nasal airway patency and breathing. The effect is local and relatively rapid, though prolonged use can lead to rebound congestion.
Approved indications
- Nasal congestion due to colds, allergies, or sinusitis
Common side effects
- Rebound nasal congestion
- Local irritation
- Headache
- Nervousness or tremor (if systemic absorption)
Key clinical trials
- Steroid Treatment for Elimination of Rebound Obstruction From Intranasal Decongestants (PHASE2)
- Evaluation of the Reliability of AAR as an Independent Tool for Surgical Indication in Nasal Obstruction
- Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis (PHASE3)
- Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant (PHASE4)
- Blocking Sphenopalatine Ganglion by Intranasal Lidocaine Spray in Partial Turbinectomy Surgeries (PHASE3)
- Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction
- Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia. (PHASE4)
- Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nasal Decongestant CI brief — competitive landscape report
- Nasal Decongestant updates RSS · CI watch RSS
- Engelhard Arzneimittel GmbH & Co.KG portfolio CI